Physician profile
Nermin Gendy
NPI 1316978851
$2,657.37
in general payments reported to CMS, 2019-2025
9 companies · $378 in 2025
The $378 reported for 2025 was more than what a typical Corneal and Contact Management provider received nationally (typical 2025 total: $227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,298 · 2020: $263 · 2021: $55.15 · 2022: $14.66 · 2023: $432 · 2024: $217 · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,027.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,027.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,732.50 | 2019-2025 | Rocklatan, Tryptyr, Rhopressa |
| Dompe US, INC. | $215.19 | 2024-2025 | Oxervate |
| Allergan, INC. | $211.26 | 2019-2021 | |
| Abbvie INC. | $125.00 | 2023 | |
| Sun Pharmaceutical Industries INC. | $109.32 | 2023-2025 | Cequa |
| Apellis Pharmaceuticals, INC. | $99.18 | 2023 | Syfovre |
| Bausch & Lomb Americas INC. | $96.64 | 2023 | Miebo |
| Kala Pharmaceuticals, INC. | $43.63 | 2021 | |
| Biotissue Holdings INC. | $24.65 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nermin Gendy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.